Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 199

The DOI matches its Crossref record.

Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients

Kotanko, Peter, Kramar, Reinhard, Devrnja, Danijela, Paschke, Eduard, Voigtla[Combining Diaeresis]nder, Till, Auinger, Martin, Demmelbauer, Klaus, Lorenz, Matthias, Hauser, Anna-Christine, Kofler, Hans-Jo[Combining Diaeresis]rg, Lhotta, Karl, Neyer, Ulrich, Pronai, Wolfgang, Wallner, Manfred, Wieser, Clemens, Wiesholzer, Martin, Zodl, Herbert, Fo[Combining Diaeresis]dinger, Manuela, Sunder-Plassmann, Gere·2004·Journal of the American Society of Nephrology

Abstract

Anderson-Fabry disease is possibly underdiagnosed in patients with end-stage renal disease. Nationwide screening was therefore undertaken for Anderson-Fabry disease among dialysis patients in Austria. Screening for alpha-galactosidase A (AGAL) deficiency was performed by a blood spot test. In patients with a positive screening test, AGAL activity in leukocytes was determined. Individuals with decreased leukocyte AGAL activity were subjected to mutation testing in the GLA gene. Fifty (90.9%) of 55 Austrian hemodialysis centers participated in this study; 2480 dialysis patients (80.1% of the Austrian dialysis population) were screened. In 85 patients, the screening test was positive (85 of 2480, 3.42%; women, 3.32%; men, 3.50%). Among these 85 patients, 4 men (in 3 of whom Anderson-Fabry disease was already known before screening) had a severely decreased and 11 subjects had a borderline low AGAL activity. Genetic testing revealed mutations associated with Fabry disease in all four men with severely decreased AGAL activity resulting in a prevalence of 0.161% for the entire study population. A nationwide screening of dialysis patients permitted detection of a hitherto unknown man with Anderson-Fabry disease. The overall prevalence among dialysis patients was at least ten times higher as compared with recent registry data. Screening programs among patients with end-stage renal disease, especially men, should be put in place to identify families with Anderson-Fabry disease who probably may benefit from specific clinical care, and perhaps from enzyme replacement therapy. In dialysis patients, however, there is no evidence to support enzyme replacement therapy at present.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.asn.0000124671.61963.1e

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 199

Metadata

Authors
Kotanko, P., Kramar, R., Devrnja, D., Paschke, E., Voigtla[Combining Diaeresis]nder, T., Auinger, M., Demmelbauer, K., Lorenz, M., Hauser, A.-C., Kofler, H.-J. D., Lhotta, K., Neyer, U., Pronai, W., Wallner, M., Wieser, C., Wiesholzer, M., Zodl, H., Fo[Combining Diaeresis]dinger, M., & Sunder-Plassmann, G.
Venue
Journal of the American Society of Nephrology
Published
2004-05
Volume
15
Issue
5
Pages
1323-1329
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2108777067
Cited by
199
References
0
FWCI
6.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients. https://app.cochat.ai/papers/10.1097/01.asn.0000124671.61963.1e
The paper
Kotanko, P., Kramar, R., Devrnja, D., Paschke, E., Voigtla[Combining Diaeresis]nder, T., Auinger, M., Demmelbauer, K., Lorenz, M., Hauser, A.-C., Kofler, H.-J. D., Lhotta, K., Neyer, U., Pronai, W., Wallner, M., Wieser, C., Wiesholzer, M., Zodl, H., Fo[Combining Diaeresis]dinger, M., & Sunder-Plassmann, G. (2004). Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000124671.61963.1e

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.